DHS MIND Metabolomics

NCT03975309 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 417

Last updated 2023-12-05

No results posted yet for this study

Summary

The study team will evaluate whether metabolomic signatures of neurocognitive decline trajectories are exacerbated by the presence of type 2 diabetes mellitus (T2D) and whether these signatures contribute in part, to ethnic disparities in cognitive decline between European Americans and African Americans with T2D.

Conditions

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH
  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Nicholette D Allred, PhD · Wake Forest University Health Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-09
Primary Completion
2023-05-23
Completion
2023-05-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03975309 on ClinicalTrials.gov